<DOC>
	<DOCNO>NCT00336973</DOCNO>
	<brief_summary>This Phase IV open-label study evaluate efficacy safety SC efalizumab adult subject ( 18 year age old ) chronic moderate bad plaque psoriasis inadequate response treatment anti-TNF agent . The study consist screening period , treatment period , observation period . All subject begin screen period ( length dependent previous anti-TNF agent treatment ) . Approximately 100 eligible subject receive treatment Day 0 Day 168 .</brief_summary>
	<brief_title>A Study Evaluate Raptiva Subjects With Chronic Moderate Worse Plaque Psoriasis Who Have Had Inadequate Response Anti-TNF Agent</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<criteria>Have chronic ( 6 month great ) moderate bad plaque psoriasis Have inadequate response least 12 week treatment antiTNF agent , inadequate response define : PGA rating moderate ( 3 ) , severe ( 4 ) , severe ( 5 ) , BSA involvement 5 % great Be candidate systemic therapy phototherapy opinion investigator Be naive efalizumab treatment Weigh 200 kg For woman childbearing potential , use method contraception acceptable investigator prevent pregnancy agree continue practice acceptable method contraception duration participation study 6 week last dose efalizumab Have history psoriatic arthritis meet one follow criterion : Is control nonsteroidal antiinflammatory drug ( NSAIDs ) ; Requires use disease modifying antirheumatic drug ( DMARDs ) , include biologics enrol study ; Please note , follow enrollment , subject require treatment DMARD , study drug treatment discontinue subject move observation period study . The subject observation period assessment perform appropriate interval per protocol Have history hypersensitivity efalizumab component Are use exclude therapy Are currently abuse alcohol illegal drug Have history ongoing uncontrolled serious bacterial , viral , fungal , atypical mycobacterial infection . This include diagnosis require 2 week therapy , endocarditis osteomyelitis , treat past 6 month . In addition , subject currently receive antibiotic , antiviral , antifungal infection suppression prophylaxis diagnosis , subject exclude . Have history opportunistic infection ( e.g. , systemic fungal infection , parasite ) Are seropositive hepatitis B antigen , hepatitis C antibody , human immunodeficiency virus ( HIV ) . Subjects undergo test screening , subject seropositive hepatitis B antigen , hepatitis C antibody , HIV exclude . Have history active tuberculosis currently undergo treatment tuberculosis . A purified protein derivative ( PPD ) test perform screen visit . Subjects positive PPD test ( due BCG vaccination ) chest xray exclude . Have presence history malignancy , include lymphoproliferative disorder . Subjects history fully resolve basal squamous cell skin cancer may enrol . Are pregnant lactate woman Have diagnosis hepatic cirrhosis , regardless cause severity Have history thrombocytopenia Have history clinically significant hemolytic unexplained anemia Have expose experimental drug treatment within 30 day 5 halflives , whichever longer , prior screen visit Have previous exposure efalizumab Have vaccinate live virus live bacteria within 14 day prior first dose efalizumab Have medical condition , judgment investigator , would jeopardize subject 's safety follow exposure study drug would significantly interfere subject 's ability comply provision protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2009</verification_date>
	<keyword>Plaque Psoriasis</keyword>
	<keyword>Raptiva</keyword>
	<keyword>Anti-TNF</keyword>
</DOC>